Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 806 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Bariatric Surgery May Reduce the Risk of Some Common Cancers December 2, 2022 FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 Happy Holidays from the OncoLink Team December 7, 2023 Load more HOT NEWS Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... Study Adds to Debate about Screening for Melanoma FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma 11 Sun Safety Myths Debunked
